Dosage form comprising drug and maltodextrin

• US 5,057,321 A
• Filed: 06/13/1990
• Issued: 10/15/1991
• Est. Priority Date: 06/13/1990
• Status: Expired due to Fees

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Edgren, David E., Bhatti, Gurdish K., Carpenter, Howard A.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): BROUILLETTE, D GABRIELLE
• Application Number:
  US07/538,046
• Time in Patent Office: 489 Days
• Field of Search: 424/473, 424/499, 424/498, 424/439, 604/892.1
• US Class Current: 424/473
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Abstract

A dosage form is disclosed comprising a drug and a maltodextrin polymer for administering to a patient a drug in need of therapy.

Claims

1. An improvement in a dosage form for delivering a drug to an animal, wherein the dosage form comprises:

(a) a wall comprising a composition permeable at least in part to the passage of fluid, which wall surrounds;

(b) a compartment;

(c) at least one exit passageway in the wall that connects the exterior of the dosage form with the composition;

(d) a composition in the compartment comprising a hydrogel that in the presence of fluid in the compartment expands and occupies space in the compartment; and

,

(e) a composition in the compartment comprising a and an osmotically effective solute, wherein the improvement comprises a maltodextrin in the composition that is compatible with the drug, aids in delivering the drug through the passageway from the compartment and comprises a 500 to 1,000,000 molecular weight and a degree of polymerization of 3 to 6,140.

2. The dosage form for delivering a drug according to claim 1, wherein the drug is a member selected from the group consisting of bromocriptine and its therapeutically acceptable salts.

3. The dosage form for delivering a drug according to claim 1, wherein the drug is a member selected from the group consisting of eldepryl and its therapeutically active salts.

4. The dosage form for drug according to claim 1, wherein the drug is a member selected from the group consisting of lisuride, pergolide, mesulergine, levodopa, carbidopa, levodopa-carbidopa, amantadine, trihexyphenidyl, benztropine, biperiden, ethopropazine, procyclidine, benztropine mesylate, trihexyphenidyl hydrochloride, procyclidine hydrochloride, and biperiden hydrochloride.

5. The dosage form for drug according to claim 1, wherein the drug is present in the composition as a drug pair, said pair comprising a member selected from the group consisting of bromocriptine, lisuride, pergolide, mesulergine, levodopa, carbidopa, levodopa-carbidopa, amantadine, deprenyl, trihexyphenidyl, benztropine, biperiden, ethopropazine, and procyclidine, and a different member selected from the group consisting of bromocriptine, lisuride, pergolide, mesulergine, levodopa, carbidopa, levodopacarbidopa, amantadine, deprenyl trihexyphenidyl, benztropine, biperiden, ethopropazine, and procyclidine.

6. An improvement in a method of drug therapy, wherein the method comprises:

(A) admitting into a patient a dosage form, which dosage form comprises;

(1) a wall comprising a composition that is permeable to the passage of fluid, which wall surrounds;

(2) a compartment;

(3) a composition in the compartment comprising a non-toxic hydrogel that imbibes fluid and expands in the presence of the imbibed fluid;

(4) a passageway in the wall connecting the exterior of the dosage form with the compartment;

(5) a composition in the compartment comprising a drug and wherein the improvement comprises a maltodextrin in the composition that is compatible with the drug for providing substantially complete delivery of the drug from the dosage form;

(B) imbibing fluid into the compartment for the hydrogel to absorb and expand thereby pushing the drug through the passageway; and

(c) administering the drug to the patient in need of the drug.

7. An improvement in a method of drug therapy according to claim 6, wherein the drug is bromocriptine administered as a prolactin inhibitor.